

Reimbursement Landscape for Molecular Testing in Non-Small Cell Lung Cancer (NSCLC)

Dave Nellesen, PhD; Katerine Dea, MSc; Annie Guerin, MSc; Kenneth W. Culver, MD; Alex Mutebi, PhD; and Anand Dalal, MBA, BSPharm

REFERENCES

1. Cancer fact sheet. World Health Organization website. who.int/mediacentre/factsheets/fs297/en/. Published February 2017. Accessed November 2017.
2. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. *CA Cancer J Clin*. 2017;67(1):7-30. doi: 10.3322/caac.21387.
3. Key statistics for lung cancer. American Cancer Society website. Revised January 4, 2018. Accessed November 28, 2017.
4. Luo SY, Lam DC. Oncogenic driver mutations in lung cancer. *Transl Respir Med*. 2013;1(1):6. doi: 10.1186/2213-0802-1-6.
5. Chan BA, Hughes BG. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. *Transl Lung Cancer Res*. 2015;4(1):36-54. doi: 10.3978/j.issn.2218-6751.2014.05.01.
6. Salgia R. Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma. *Expert Rev Mol Diagn*. 2016;16(7):737-749. doi: 10.1080/14737159.2016.1181545.
7. Barlesi F, Mazieres J, Merlio JP, et al; Biomarkers France contributors. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). *Lancet*. 2016;387(10026):1415-1426. doi: 10.1016/S0140-6736(16)00004-0.
8. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. *JAMA*. 2014;311(19):1998-2006. doi: 10.1001/jama.2014.3741.
9. Targeted therapy drugs for non-small cell lung cancer. American Cancer Society website. cancer.org/cancer/non-small-cell-lung-cancer/treating/targeted-therapies.html. Revised June 23, 2017. Accessed November 28, 2017.
10. Tafinlar (dabrafenib) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2017. accessdata.fda.gov/drugsatfda_docs/label/2017/202806s006lbl.pdf. Accessed December 11, 2017.
11. Mekinist (trametinib) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2017. accessdata.fda.gov/drugsatfda_docs/label/2017/204114s005lbl.pdf. Accessed December 11, 2017.
12. Cabozantinib in patients with RET fusion-positive advanced non-small cell lung cancer and those with other genotypes: ROS1 or NTRK fusions or increased MET or AXL activity. ClinicalTrials.gov website. clinicaltrials.gov/ct2/show/NCT01639508. Updated February 14, 2017. Accessed November 28, 2017.
13. Clinical study of oral cMET inhibitor INC280 in adult patients with advanced non-small cell lung cancer who have received one or two prior lines of therapy. ClinicalTrials.gov website. clinicaltrials.gov/ct2/show/NCT02414139. Updated November 13, 2017. Accessed November 28, 2017.
14. A trial of AP32788 in non-small cell lung cancer. ClinicalTrials.gov website. clinicaltrials.gov/ct2/show/NCT02716116. Updated September 6, 2017. Accessed November 28, 2017.
15. FDA grants regular approval to dabrafenib and trametinib combination for metastatic NSCLC with BRAF V600E mutation. FDA website. fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm564331.htm. Updated June 22, 2017. Accessed November 28, 2017.
16. Libra M, Malaponte G, Navolanic PM, et al. Analysis of BRAF mutation in primary and metastatic melanoma. *Cell Cycle*. 2005;4(10):1382-1384.
17. Satzger I, Marks L, Kerick M, et al. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma. *Oncotarget*. 2015;6(35):37895-37905. doi: 10.18632/oncotarget.5634.
18. Luk PP, Yu B, Ng CC, et al. BRAF mutations in non-small cell lung cancer. *Transl Lung Cancer Res*. 2015;4(2):142-148. doi: 10.3978/j.issn.2218-6751.2014.08.08.
19. Planchard D, Besse B, Groen HJM, Souquet PJ, Quoix EA, Baik CS. An open-label phase II trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E-mutant advanced non-small cell lung cancer. *J Clin Oncol*. 2016;34(15 suppl); abstract 107. doi: 10.1200/JCO.2016.34.15_suppl.107#affiliationsContainer.
20. Planchard D, Groen H, Kim T, et al. Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC). *J Clin Oncol*. 2015;33(15 suppl);abstr 8006. doi: 10.1200/jco.2015.33.15_suppl.8006.
21. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]) for Non-Small Cell Lung Cancer (V.1.2018). National Comprehensive Cancer Network, Inc 2017. All rights reserved. Accessed November 28, 2017. To view the most recent and complete version of the guideline, go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK[®], NCCN[®], NCCN GUIDELINES[®], and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.
22. Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. *Ann Oncol*. 2011;22(12):2616-2624. doi: 10.1093/annonc/mdr489.
23. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology [published correction appears in *J Thorac Oncol*. 2013;8(10):1343]. *J Thorac Oncol*. 2013;8(7):823-859. doi: 10.1097/JTO.0b013e318290868f.
24. Cancer Care Quality Program Treatment Pathways; revised: updates effective August 29, 2017. Anthem website. anthem.aimoncology.com/pdf/pathways/Cancer_Pathways_Clinical_Detail.pdf. Accessed November 28, 2017.
25. Spicer J, Tischer B, Peters M. EGFR mutation testing and oncologist treatment choice in advanced nscl: global trends and differences. In: Proceedings from the European Lung Cancer Conference 2015; April 15-18, 2015; Geneva, Switzerland. Abstract LBA2_PR.
26. Ray T. Survey shows more NSCLC patients getting EGFR testing, but results often don't inform care. GenomeWeb website. genomeweb.com/molecular-diagnostics/survey-shows-more-nsclc-patients-getting-egfr-testing-results-often-dont. Published April 27, 2015. Accessed November 28, 2017.
27. Ray T. Precision medicine in oncology gets more support with 13K-patient meta-analysis. GenomeWeb website. genomeweb.com/cancer/precision-medicine-oncology-gets-more-support-13k-patient-meta-analysis. Published May 19, 2016. Accessed November 28, 2017.
28. Ray T. In 2015, precision medicine options grew; FDA, labs still at odds; payment remained mostly elusive. GenomeWeb website. genomeweb.com/molecular-diagnostics/2015-precision-medicine-options-grew-fda-labs-still-odds-payment-remained. Published December 31, 2015. Accessed November 28, 2017.
29. Ray T. At workshop, FDA gathers input on how to regulate NGS panels to guide cancer treatment. GenomeWeb website. genomeweb.com/molecular-diagnostics/workshop-fda-gathers-input-how-regulate-ngs-panels-guide-cancer-treatment. Published February 29, 2016. Accessed November 28, 2017.
30. Ray T. Palmetto draft LCD of cancer genomic profiling in NSCLC is good first step, say NGS test providers. GenomeWeb website. genomeweb.com/reimbursement/palmetto-draft-lcd-cancer-genomic-profiling-nsclc-good-first-step-say-ngs-test. Published February 2, 2015. Accessed November 28, 2017.
31. Newbern E. AIM specialty health, informedDNA partner to provide genetic testing guidance to payors. GenomeWeb website. genomeweb.com/business-news/aim-specialty-health-informeddna-partner-provide-genetic-testing-guidance-payors. Published May 6, 2016. Accessed November 28, 2017.
32. Bunn JPA. What testing is needed for clinical treatment? In: Proceedings from the 16th

MOLECULAR TESTING - REFERENCES

- World Conference on Lung Cancer; September 6-9, 2015; Denver, CO. Abstract S84.
33. Jamal-Hanjani M, De Bruin E, Wilson G, et al. Intratumor heterogeneity and the detection of potential driver mutations in cfDNA in a NSCLC cohort using UltraSEEK™. *Cancer Res.* 2015;75(suppl 15, abstr 5249). cancerres.aacrjournals.org/content/75/15_Supplement/5249.
 34. Benesova L, Belsanova B, Minarikova P, et al. Validation of a simple low-cost method to monitor ctDNA in patients with solid cancers. *Cancer Res.* 2015;75(suppl 15; abstr 2406). cancerres.aacrjournals.org/content/75/15_Supplement/2406.
 35. Smalley SK, Gale D, Lawson ARJ, et al. Assessing the clinical applications of ctDNA in patients with advanced stage metastatic cancer using our enhanced TAm-Seq platform. *Mol Cancer Ther.* 2016;14(12 Suppl 2; abstr B7). mct.aacrjournals.org/content/14/12_Supplement_2/B7.
 36. Mehrad M, Nikiforova M, Bittar HT, Dacic S. Next generation sequencing approach to non-small cell lung carcinoma testing yields more actionable results [published online December 8 2017]. *Arch Pathol Lab Med.* 2017; doi: 10.5858/arpa.2017-0046-OA.
 37. Esposito A, Criscitiello C, Locatelli M, Milano M, Curigliano G. Liquid biopsies for solid tumors: understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies. *Pharmacol Ther.* 2016;157:120-124. doi: 10.1016/j.pharmthera.2015.11.007.
 38. Ileana EE, Wistuba, II, Izzo JG. From uniplex to multiplex molecular profiling in advanced non-small cell lung carcinoma. *Cancer J.* 2015;21(5):413-424. doi: 10.1097/PPO.0000000000000150.
 39. Janku F, Madwani K, Zhang S, et al. Ultra-deep next-generation sequencing of plasma cell-free (cf) DNA from patients with advanced cancers. *J Clin Oncol.* 2016;34(suppl 15; abstr 11537). doi: 10.1200/JCO.2016.34.15_suppl.11537#affiliationsContainer.
 40. Murphy DM, Angiuoli SV, Chesnick B, et al. A comprehensive noninvasive approach for the stratification of lung cancer patients for targeted therapies. *J Clin Oncol.* 2015;33(suppl 15; abstr e22086). doi: 10.1200/jco.2015.33.15_suppl.e22086.
 41. Hagemann IS, Devarakonda S, Lockwood CM, et al. Clinical next-generation sequencing in patients with non-small cell lung cancer. *Cancer.* 2015;121(4):631-639. doi: 10.1002/cncr.29089.
 42. Sakairi Y, Sato K, Itoga S, et al. Transbronchial biopsy needle rinse solution used for comprehensive biomarker testing in patients with lung cancer. *J Thorac Oncol.* 2014;9(1):26-32. doi: 10.1097/JTO.0000000000000024.
 43. Lei J, Hsu J, Jen P, et al. KRAS, BRAF, and EGFR mutational analysis in ovarian, colon, and lung cancers by highly multiplex PCR/barcoded-magnetic-bead (BMB) suspension-array assays. *Cancer Res.* 2014;74(suppl 19; abstr 4663). cancerres.aacrjournals.org/content/74/19_Supplement/4663.
 44. Janku F, Falchook GS, Piha-Paul SA, et al. Droplet digital PCR detection and longitudinal monitoring of BRAF mutations in cell-free urinary DNA of patients with metastatic cancers or Erdheim-Chester disease. *Cancer Res.* 2014;74(suppl 19; abstr LB-170). aacrjournals.org/content/74/19_Supplement/LB-170.
 45. Wang J, Bai H, Duan J, et al. Parallel detections of multi-driver genes in plasma DNA for patients with advanced non-small cell lung cancer (NSCLC). *J Clin Oncol.* 2014;32(suppl 15; abstr e19113). doi: 10.1200/jco.2014.32.15_suppl.e19113.
 46. Tambo Y, Katayama R, Yanagitani N, et al. The feasibility to use minimal tumor samples for mutation analysis by multiplex PCR-based assay. *J Clin Oncol.* 2014;32(suppl 15; abstr e22060). doi: 10.1200/jco.2014.32.15_suppl.e22060.
 47. Carcereny E, Centeno C, Munoz A, et al. Is cytology sample from endobronchial ultrasound (EBUS)-guided transbronchial needle aspiration (TBNA) sufficient for analysis of major known driver mutations in non-small cell lung cancer (NSCLC)? In: Proceedings from the American Society of Clinical Oncology; May 30-June 3, 2014; Chicago, IL. Abstract e22110.
 48. Janku F, Vibat CRT, Falchook GS, Piha-Paul SA, Naing A. Longitudinal monitoring of BRAF V600E mutation in urinary cell-free DNA of patients with metastatic cancers. *J Clin Oncol.* 2014;32(suppl 15; abstr e22175). doi: 10.1200/jco.2014.32.15_suppl.e22175.
 49. Oxnard GR, Binder A, Jänne PA. New targetable oncogenes in non-small-cell lung cancer. *J Clin Oncol.* 2013;31(8):1097-1104. doi: 10.1200/JCO.2012.42.9829.
 50. Janku F, Falchook GS, Piha-Paul SA, et al. Detection and monitoring of BRAF and KRAS mutations in cell-free urinary DNA of metastatic cancer patients by droplet digital PCR. *Mol Cancer Ther.* 2014;12(suppl 11; abstr B175). mct.aacrjournals.org/content/12/11_Supplement/B175.
 51. Huang HJ, Claes B, Falchook GS, et al. BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics prototype platform. *Mol Cancer Ther.* 2014;12(suppl 11; abstr A202). mct.aacrjournals.org/content/12/11_Supplement/A202.
 52. Zhao W, Long S, Burton G, et al. Molecular profiling by next-generation sequencing in non-small cell lung cancer. *Am J Clin Pathol.* 2013;140(suppl 1):A065. doi: 10.1093/ajcp/140.suppl1.065.
 53. Sagan C, Vallee A, Denis MG. Efficient detection of EGFR, KRAS, and BRAF mutations in cell-free DNA from pleural effusions. *J Clin Oncol.* 2013;31(suppl 15; abstr e19151). doi: 10.1200/jco.2013.31.15_suppl.e19151.
 54. Asiedu M, Molina JR, Jen J, Jang JS, Roden A. Review of 200 consecutive patients with mutation profiling in a lung cancer individualized medicine clinic. *J Clin Oncol.* 2013;31(suppl 15; abstr e19013). doi: 10.1200/jco.2013.31.15_suppl.e19013.
 55. Buettner R, Koenig K, Peifer M, et al. High-throughput parallel amplicon sequencing of common driver mutations from FFPE lung cancer samples in molecular pathologic routine diagnostics for a regional health care provider network. *J Clin Oncol.* 2013;31(suppl 15; abstr e12517). doi: 10.1200/jco.2013.31.15_suppl.e12517.
 56. Bedard PL, Oza AM, Tsao M-S, Leigh NB, Shepherd FA. Princess Margaret Cancer Centre (PMCC) Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) using genotyping and targeted next-generation sequencing (NGS). *J Clin Oncol.* 2013;31(suppl 15; abstr 11002). doi: 10.1200/jco.2013.31.15_suppl.11002.
 57. Swanton C, Govindan R. Clinical implications of genomic discoveries in lung cancer. *N Engl J Med.* 2016;374(19):1864-1873. doi: 10.1056/NEJMra1504688.
 58. MacLean E, Louder A, Saverno K, et al. Molecular testing patterns in metastatic non-small-cell lung cancer. *Am J Manag Care.* 2016;22(2):e60-e67.
 59. Biocept BRAF liquid biopsy test. GenomeWeb website. genomeweb.com/resources/new-product/biocept-braf-liquid-biopsy-test. Published July 14, 2015. Accessed November 28, 2017.
 60. Curtin C. Sequencing-based gene panels help diagnose, guide treatment, AACC presenters say. GenomeWeb website. genomeweb.com/sequencing-technology/sequencing-based-gene-panels-help-diagnose-guide-treatment-aacc-presenters-say. Published July 29, 2015. Accessed November 28, 2017.
 61. Study finds targetable mutations more frequent in young lung cancer patients than old ones. GenomeWeb website. genomeweb.com/cancer/study-finds-targetable-mutations-more-frequent-young-lung-cancer-patients-old-ones. Published December 17, 2015. Accessed November 28, 2017.
 62. Ashford M. Survey of lab community predicts greater adoption of liquid biopsy; increasing focus on NGS. GenomeWeb website. genomeweb.com/cancer/survey-lab-community-predicts-greater-adoption-liquid-biopsy-increasing-focus-ngs. Published October 7, 2015. Accessed November 28, 2017.
 63. Ashford M. UPenn center for personalized Dx expands tumor NGS menu, reports concordance with single-gene tests. GenomeWeb website. www.genomeweb.com/sequencing-technology/upenn-center-personalized-dx-expands-tumor-ngs-menu-reports-concordance-single. Published April 18, 2016. Accessed November 28, 2017.
 64. PRMA insights: market access success for companion diagnostic-drug pairings in oncology. PRMAConsulting website. prmaconsulting.com/companion-diagnostics-oncology/companion-diagnostics-oncology-insights-brochure.pdf. Accessed November 28, 2017.
 65. De Abreu FB, Schwab MC, Black CC, et al. Genotyping multiple somatic mutations in non-small cell lung cancer and colorectal carcinoma using the snapshot technology. *J Mol Diagn.* 2013;15(6):843-945; abstr ST71. jmd.amjpathol.org/article/S1525-1578(13)00181-5/pdf.
 66. Al-Kateb H, Hageman I, Cottrell CE, et al. Spectrum of actionable variants identified by clinical targeted next-generation sequencing in cancer. *J Mol Diagn.* 2013;15(6):843-945; abstr ST15. jmd.amjpathol.org/article/S1525-1578(13)00181-5/pdf.
 67. Farilla L, Reynolds P, Marola J, et al. Development and validation of a high sensitivity SNaP-shot assay for mutation profiling of non-small cell lung cancer (NSCLC) patients. *J Mol Diagn.* 2012;14(6):637-748. jmd.amjpathol.org/article/S1525-1578(12)00211-5/pdf.
 68. Corless CL. Next generation sequencing: what will it mean for the pathologist? *J Pathol.* 2015;237:S11. doi: 10.1159/000480089.
 69. Cong L, Zhang J, Siple J, Ruggiero P, Fernandes H. Utility of targeted next-generation sequencing assays in a routine molecular pathology laboratory. *J Mol Diagn.* 2015;17(6):851. doi: 10.1136/jclinpath-2017-204440.
 70. Carter JH, Miller JA, Maleki Z. Molecular profiling of malignant pleural effusion in metastatic non-small cell lung carcinoma. *Lab Invest.* 2016;96(S1):86-125. doi: 10.1513/AnnalsATS.201609-709OC.
 71. Beaubier N, Mateescu V, Elvin JA. Clinical utility of targeted next generation sequencing in lung cancer. *Lab Invest.* 2016;96(S1):467-488. doi: 10.1038/labinvest.2016.22.
 72. Pierce KJ, Peterson JD, De Abreu FB, et al. Targeted clinical genotyping of non-small cell lung cancers (NSCLC) using next-generation sequencing. *J Mol Diagn.* 2014;16(6):756-757. abstr ST49. jmd.amjpathol.org/article/S1525-1578(14)00173-1/pdf.
 73. Froyen G, Broekmans A, Hillen F, et al. Validation and application of a custom-designed

MOLECULAR TESTING - REFERENCES

- targeted next-generation sequencing panel for the diagnostic mutational profiling of solid tumors. *PLoS ONE*. 2016;11(4):e0154038. doi: 10.1371/journal.pone.0154038.
74. Sorensen JB, Grauslund M, Melchior L. Use of next generation sequencing to distinguish origin of poorly differentiated carcinomas in the lung from carcinomas in other organs. *J Thorac Oncol*. 2015;10(9 suppl 2):S709-S710. doi: 10.1016/S1556-0864(16)30012-0.
 75. Cooper W, Kraitsek S, Selinger C. Is targeted next generation sequencing superior to older methods at identifying actionable mutations in selected NSCLC patients? *J Thorac Oncol*. 2015;10(9 suppl 2):S708. doi: 10.1016/S1556-0864(16)30012-0.
 76. La Fleur L, Moens L, Falk-Sorqvist E. Mutation profiling by targeted next-generation sequencing for diagnostics and patient cohort screening in FFPE NSCLC samples. *J Thorac Oncol*. 2015;10(9 SUPPL. 2):S697
 77. Mack PC, Gandara DR, Lara JP. Identification of actionable tumor alterations in circulating cell-free tumor DNA (CF DNA) using digital sequencing from NSCLC patients. *J Thorac Oncol*. 2015;10(9 suppl 2):S249-S250. doi: 10.1016/S1556-0864(16)30010-7.
 78. Villaflor V, Won B, Nagy B. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. *J Thorac Oncol*. 2015;10(9 suppl 2): S248-S249. doi: 10.1016/S1556-0864(16)30010-7.
 79. Lara-Torres CO. Communicating with pathologists about molecular testing. *J Thorac Oncol*. 2015;10(9 suppl 2):S84-S85. doi: 10.1016/S1556-0864(16)30009-0.
 80. Choughule A, Trivedi V, Chandrani P. Bench to bedside detection of actionable genotypes by snapshot for lung cancer panel. *J Thorac Oncol*. 2015;10(9 suppl 2): S521-S522. doi: 10.1016/S1556-0864(16)30013-2.
 81. Kaderbhai CG, Boidot R, Beltjens F, et al. Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer. *Oncotarget*. 2016;7(17):24860-24870. doi: 10.18632/oncotarget.8391.
 82. Tsui DW, Berger ME. Profiling non-small cell lung cancer: from tumor to blood. *Clin Cancer Res*. 2016;22(4):790-792. doi: 10.1158/1078-0432.CCR-15-2514.
 83. Center for Medical Technology Policy releases reimbursement guidelines for NGS oncology testing. GenomeWeb website. genomeweb.com/reimbursement/center-medical-technology-policy-releases-reimbursement-guidelines-ngs-oncology. Published April 17, 2015. Accessed November 28, 2017.
 84. UnitedHealthcare covers Foundation Medicine test for metastatic lung cancer. GenomeWeb website. genomeweb.com/cancer/unitedhealthcare-covers-foundation-medicine-test-metastatic-lung-cancer. Published December 21, 2015. Accessed November 28, 2017.
 85. 2015 ACMG Annual Clinical Genetics Meeting. The next generation of genomic testing: billing and reimbursement in the genomic era. National Coordinating Center for the Regional Genetics Networks website. www.nccrg.org/docs/NCC/ACA/Resources/The_Next_Generation_Of_Genomic_Testing.pdf. Published March 2015. Accessed November 28, 2017.
 86. Deverka PA, Dreyfus JC. Clinical integration of next generation sequencing: coverage and reimbursement challenges. *J Law Med Ethics*. 2014;42 suppl 1:22-41. doi: 10.1111/jlme.12160.
 87. Green Park Collaborative. Initial medical policy and model coverage guidelines for clinical next generation sequencing in oncology. Center for Medical Technology Policy website. cmtpnnet.org/docs/resources/Full_Release_Version_August_13__2015.pdf. Published August 17, 2015. Accessed November 28, 2017.
 88. Hager M. Experts discuss issues surrounding reimbursement, implementation of genomic tests. GenomeWeb website. genomeweb.com/reimbursement/experts-discuss-issues-surrounding-reimbursement-implementation-genomic-tests. Published June 25, 2015. Accessed November 28, 2017.
 89. Murgu S, Colt H. Role of the pulmonologist in ordering post-procedure molecular markers in non-small-cell lung cancer: implications for personalized medicine. *Clin Lung Cancer*. 2013;14(6):609-626. doi: 10.1016/j.clcc.2013.04.002.
 90. Bunn PA. What testing is needed for clinical treatment? *J Thorac Oncol*. 2015;10(9):S66-S172; abstr ED11.01 [jto.org/article/S1556-0864\(16\)30009-0/pdf](http://jto.org/article/S1556-0864(16)30009-0/pdf)
 91. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. *J Mol Diagn*. 2013;15(4):415-453. doi: 10.1016/j.jmoldx.2013.03.001.
 92. College of American Pathologists, International Association for the Study of Lung Cancer, Association for Molecular Pathology. Molecular testing guideline for selection of lung cancer patients – revision 2016 draft recommendations – CONFIDENTIAL. iaslc.org/sites/default/files/wysiwyg-assets/5-20160616capiaslcamlungguideline-2016draftrecommendations_ocpfinal.pdf. Accessed November 28, 2017.
 93. Leighl NB, Rekhtman N, Biermann WA, et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology guideline. *J Clin Oncol*. 2014;32(32):3673-3679. doi: 10.1200/JCO.2014.57.3055.
 94. Majority of lung cancer treatment decisions are not guided by patient's genetic makeup, according to new international survey [news release]. Ridgefield, CT: Boehringer-Ingelheim; April 22, 2015. us.boehringer-ingenheim.com/news_events/press_releases/press_release_archive/2015/4-22-2015-majority-lung-cancer-treatment-decisions-not-guided-patients-genetic-makeup-new-international-survey.html. Accessed November 28, 2017.
 95. Beaubier N, Mateescu V, Elvin JA, Ali SM, Morency E, Nayar R. Clinical utility of targeted next generation sequencing in lung cancer. Presented at: 105th Annual Meeting of the United States and Canadian Academy of Pathology; March 12-18, 2016; Seattle, WA. Conference Publication: 96 468A; abstr 1853. www.nature.com/articles/labinvest201622.pdf.
 96. Cong L, Zhang J, Siple J. Utility of targeted next-generation sequencing assays in a routine molecular pathology laboratory. *J Mol Diagn*. 2015;17(6):851; abstr TT33. [jmd.amjpathol.org/article/S1525-1578\(15\)00191-9/pdf](http://jmd.amjpathol.org/article/S1525-1578(15)00191-9/pdf).
 97. Janku F, Huang HJ, Ramzanali NM. Ultra-deep next-generation sequencing of plasma cell-free (cf) DNA from patients with advanced cancers. *J Clin Oncol* 2016;34(suppl 15; abstr 11537). doi: 10.1200/JCO.2016.34.15_suppl.11537
 98. Murphy DM, Angiuoli SV, Chesnick B. A comprehensive noninvasive approach for the stratification of lung cancer patients for targeted therapies. *J Clin Oncol*. 2015;33(suppl 15; abstr 8062). doi: 10.1200/jco.2015.33.15_suppl.8062. Wang J, Bai H, Duan J. Parallel detections of multi-driver genes in plasma DNA for patients with advanced non-small cell lung cancer (NSCLC). *J Clin Oncol*. 2014;32(suppl 15; abstr e19113). doi: 10.1200/jco.2014.32.15_suppl.e19113 .
 99. Legendre BL, Richardson K, Falchook GS, et al. BRAF and KRAS mutation testing in plasma cell-free DNA with ICE COLD-PCR in patients with advanced cancers. *J Clin Oncol*. 2014;32(suppl 15; abstr e22147).
 100. FDA approves first blood test to detect gene mutation associated with non-small cell lung cancer [news release]. Silver Spring, MD: FDA; June 1, 2016. fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm504488.htm. Accessed November 28, 2017.
 101. Molecular Diagnostic Services (MolDX). Noridian website. med.noridianmedicare.com/web/jeb/policies/molDX. Updated January 3, 2018. Accessed January 30, 2018.
 102. Drilon A, Wang L, Arcila ME, et al. Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches. *Clin Cancer Res*. 2015;21(16):3631-3639. doi: 10.1158/1078-0432.CCR-14-2683.
 103. Suh JH, Johnson A, Albacker L, et al. Comprehensive genomic profiling facilitates implementation of the National Comprehensive Cancer Network Guidelines for lung cancer biomarker testing and identifies patients who may benefit from enrollment in mechanism-driven clinical trials. *Oncologist*. 2016;21(6):684-691. doi: 10.1634/theoncologist.2016-0030.
 104. Ali SM, Ou S-HI, He J, et al. Identifying ALK rearrangements that are not detected by FISH with targeted next-generation sequencing of lung carcinoma. *J Clin Oncol* 2014;32(suppl 15; abstr 8049). doi: 10.1200/jco.2014.32.15_suppl.8049 .
 105. An international survey assessed EGFR mutation testing rates and treatment practices in a specific type of lung cancer. Boehringer Ingelheim website. boehringer-ingenheim.us/sites/us/files/documents/kantar-health-survey-infographic.pdf. Published 2015. Accessed November 28, 2016.
 106. Association for Molecular Pathology (AMP), International Association for the Study of Lung Cancer. Molecular Testing Guideline for Selection of Lung Cancer Patients – Revision 2016 Draft Recommendations [page 4, table 2] www.iaslc.org/sites/default/files/wysiwyg-assets/5-20160616capiaslcamlungguideline-2016draftrecommendations_ocpfinal.pdf. Accessed January 30, 2018.
 107. Ray T. In 2015, precision medicine options grew; FDA, labs still at odds; payment remained mostly elusive. GenomeWeb website. genomeweb.com/molecular-diagnostics/2015-precision-medicine-options-grew-fda-labs-still-odds-payment-remained. Published December 31, 2015. Accessed November 28, 2017.
 108. NextGxDx enters health insurance market with solutions to bring transparency to genetic testing reimbursement. Nashville, TN: PRNewswire; April 5, 2016. prnewswire.com/news-releases/nextgxdx-enters-health-insurance-market-with-solutions-to-bring-transparency-to-genetic-testing-reimbursement-300245918.html. Accessed November 28, 2016.